We applied our 20 years of epigenomic expertise to help Universal Diagnostics SA develop an early-detection cancer assay. We created a unique, customized approach using DNA methylation technologies
for biomarker discovery and subsequent biomarker validation using liquid biopsies. The result was a blood-based methyl-seq cancer early detection assay for colorectal cancer (CRC).
Biomarkers for all grades of CRC were identified, validated and monitored, making it possible for each patient to receive the best medical attention available.
 |
Capturing biomarkers in real-time with liquid biopsy
Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in real-time in the risk population. |
We helped identify the best sample prep options in terms of quantity, quality, reproducibility and high-throughput for regular screening of cfDNA from plasma. |
 |
DNA methylation for cancer classification Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarkers. |
Using our WGBS/EM-seq service, UniversalDx identified DNA methylation patterns associated with each CRC grade. |
 |
Validating biomarkers for performance
Once a pool of potential biomarkers was available, we identified the best performers. |
Thanks to our Targeted Methyl-seq service, UniversalDx narrowed down the candidates, and we validated a set of biomarkers
that performs reliably with an NGS assay. |
“With the help of Diagenode’s experts, we are developing blood tests that detect cancer in its earliest stages.”
Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics
